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SHORT RUNNING HEAD: 




Presentation of the first universal structured reporting tool to document all neuroblastoma 
surgical procedures and their outcome(s), created by a unique collaboration of three 
international Pediatric Oncological Cooperative Groups, to facilitate treatment planning, 
recording of post-operative metrics (Clavien-Dindo) and analysis of the crucial role of surgery 
in neuroblastoma.  
  








Objective:  To create the first structured surgical report form for neuroblastoma (NBL) with 
international consensus, to permit standardized documentation of all NBL-related surgical 
procedures and their outcomes. 
Summary Background Data:  NBL, the most common extracranial solid malignant tumor in 
children, covers a wide spectrum of tumors with significant differences in anatomical 
localization, organ or vessel involvement and tumor biology. Complete surgical resection of 
the primary tumor is an important part of NBL treatment, but may be hazardous, prone to 
complications and its role in high-risk disease remains debated. Various surgical guidelines 
exist within the protocols of the different cooperative groups, although there is no 
standardized operative report form to document the surgical treatment of NBL.  
Methods: After analyzing the treatment protocols of the SIOPEN, COG and GPOH pediatric 
cooperative groups, important variables were defined to completely describe surgical biopsy 
and resection of NBL and their outcomes. All variables were discussed within the Surgical 
Committees of SIOPEN, COG and GPOH. Thereafter, joint meetings were organized to 
obtain intercontinental consensus. 
Results:  The “International Neuroblastoma Surgical Report Form” (INSRF) provides a 
structured reporting tool for all NBL surgery, in every anatomical region, documenting all 
Image Defined Risk Factors and structures involved, with obligatory reporting of 
intraoperative and 30 day-postoperative complications.  
Conclusion:  The INSRF is the first universal form for the structured and uniform reporting of 
NBL-related surgical procedures and their outcomes, aiming to facilitate the postoperative 
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COG: Children’s Oncology Group 
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Neuroblastoma (NBL), an embryonal sympathetic nervous system tumor, is the most 
common cancer in infants and the most common extracranial solid malignant tumor in 
children (1) (2) (3) (4) , with an overall age-standardized incidence rate of 10.2 to 10.9 cases 
per million children in the USA and Europe respectively. (2) (3) NBL accounts for 6% of all 
childhood cancers (1) and 12-15% of cancer-related deaths under the age of 15 years. (3, 5)  
NBL has a broad spectrum of clinical behavior that correlates with a number of clinical and 
biological features. (6) Following international consensus, NBL is treated multimodally, 
according to the pretreatment International NBL Risk Group (INRG) classification system. (6)  
This system identifies four risk categories (very low-, low-, intermediate- and high-risk) taking 
into account the tumor stage, age at diagnosis, histology, grade, MYCN status, chromosomal 
aberrations and tumor cell ploidy. (6) To uniformly stage NBL before the initiation of 
treatment, the INRG-Staging-System (INRGSS) was developed, based upon tumor imaging 
and on the absence or presence of preoperative “Image-Defined Risk Factors” (IDRFs). (7) 
These IDRFs describe the various locations where NBL may occur and the vital structures 
(organs, vascular and neural structures) that may be involved by the tumor. (8)  
As NBL originates from developmental anomalies of the neural crest, there is a wide 
spectrum of locations where the primary tumor may occur, related to the sympathetic 
nervous system anatomy. (3) The anatomical distribution of NBL can be described by 
compartmental classification (Figure 1) (4) and most primary tumors arise in the abdominal 
compartment (adrenal gland 48%, extra-adrenal retroperitoneum 25%). The thoracic location 
of NBL is less frequent accounting for 16-20%, and the cervical and pelvic compartments 
account for three to five percent of NBL respectively. (4) Recent studies suggest that the 
sympathetic anatomical location of NBL may also be relevant as a prognostic factor. (4)  
 







Local control of the primary tumor by complete surgical resection is an important part of NBL 
treatment. The role of surgical resection in high-risk NBL however remains debated as it is 
difficult to study, due to the relative rarity of NBL, its different localizations, heterogenous 
presentations (4) and internationally varying treatment protocols, incorporating postoperative 
radiation therapy to aid in local control. Especially for high-risk NBL, divergent results have 
been reported on the role, extent and timing of surgical resection. (9) (10) (11) In addition, 
the reporting of surgical treatment of NBL is not standardized and may vary considerably.  
As the surgical reporting of a postoperative residual primary tumor may influence 
postoperative irradiation planning in future high-risk NBL treatment protocols, the 
documentation of NBL surgery and its immediate outcomes must be optimized.  
Improving the quality of surgical reporting will also facilitate the analysis of the role, extent 
and timing of surgical treatment in NBL. Therefore we aimed to develop a uniform, structured 
report form to document every NBL-related surgical procedure. 
  








MATERIAL AND METHODS 
A working party group within the Surgical Committee of SIOPEN, under the joint leadership 
of the first and the last author, started in 2014 with the NBL-Surgical Report Form-project. 
After the approval of the members of the Surgical Committees of the Children’s Oncology 
Group (COG) and of the German Association of Paediatric Oncology and Haematology 
(GPOH), the surgical guidelines in the different study protocols of SIOPEN, COG and GPOH 
were analyzed to identify the variables needed to completely describe the mode and impact 
of surgical interventions (biopsy and resection) for NBL, as well as the outcomes of the 
surgical intervention. All crucial variables describing the timing, mode, management of IDRFs 
and the operative results were listed, defined and discussed within the working group of the 
SIOPEN Surgical Committee.  
Thereafter, a first draft of a structured report form was developed, in different steps, 
discussing each step within the SIOPEN Surgical Committee, until consensus was reached 
on the Neuroblastoma Surgical Report Form (NSRF). In parallel, the same action was 
performed within the Surgical Committees of COG and GPOH. Over the years, several joint 
meetings were organized to discuss and standardize the NSRF draft together with the 
members of all three Surgical Committees in order to obtain intercontinental consensus. After 
its conception, the International NSRF was tested and used in clinical practice by the 
members of the core working party group, confirming its feasibility and completeness, 
  









The International Neuroblastoma Surgical Report Form (INSRF) is the first universal report 
form to document every NBL-related surgical procedure (biopsy and resection) and contains 
five sections on five pages, see Figure 2. The first four sections are ideally completed by the 
surgeon immediately after the surgical intervention.  
The first section of the INSRF includes coded patient and treatment protocol details.  
The second section involves the type, timing and date of the intervention, the surgical 
approach (open or minimally invasive surgery) and the extent of the biopsy or resection, 
including four options, defined with international consensus: “complete resection” ; “minimal 
residue” (defined as “less than five cubic centimeter of tumor remaining”) ; “incomplete 
resection” (defined as “five or more cubic centimeter residue”) or “other”, for which detailed 
information is then fully requested.  
The localisation of the primary tumor is uniformly reported by the indication of the anatomical 
compartment(s) (cervical, cervico-thoracic, thoracic, thoraco-abdominal, abdominal/pelvic). 
Surgical metastatic sites are reported by organ. Preoperative plan discussion at a 
multidisciplinary tumor board is recorded.  
In addition, section two incorporates the description of all preoperative post-chemotherapy 
IDRFs, according to the definitions of terms to describe relationships between primary tumor 
and vital structures stated in the INRG Guidelines for Imaging and Staging of Neuroblastic 
Tumors. (8)  
The surgical findings are documented in the third section of the INSRF. Here, the surgeon 
indicates and documents all organs and structures involved, as well as their individual 
intraoperative management, by the use of agreed-upon and well-defined surgical 
terminology. To document vessel involvement, the surgeon can differentiate between two 
types: ‘adherence’ is defined as vessel involvement of <50% of the circumference, and 







‘encasement’ as 50-100% of the vessel circumference. (12) If a blood vessel was injured, the 
surgeon specifies how this injury was managed during the surgical intervention and if 
macroscopic residual tumor remained at this location or not. The side of the vessel is 
indicated and in case of bilateral involvement, detailed specifications per side can be added 
as free text. In the same fashion, organ involvement is to be reported. When appropriate, the 
side of involvement is documented and in case of bilateral involvement detailed 
specifications per side can be added as free text. The type of organ involvement is stated as 
‘adherence’ (defined as close contact between tumor and organ but with a distinct plane of 
dissection) or ‘infiltration’ (no distinct dissection plane, necessitating partial (even minimal) 
organ resection). The surgeon then documents how the organ involvement was treated by 
the use of one out of three options (“no organ resection” – “partial organ resection” or 
“complete organ resection”) and whether macroscopic residual tumor was left or not. Liver 
involvement is described using the segmental classification, as described by Couinaud.(13)  
The fourth section of the INSRF documents all intraoperative complications and the 
management/intervention(s) performed to solve the complication, with enough free text 
space to add detailed specifications or remarks.  
Possible intraoperative deviations from the preoperative plan discussed at a multidisciplinary 
tumor board can be indicated and described in detail. 
The last section of the INSRF is to be completed by the surgeon one month after the 
operation. This final part describes the postoperative complications, related to the surgery, 
during the first 30 days after the operation, see Figure 2. To standardize the reporting of 
postoperative outcomes, the Clavien-Dindo classification was adopted, with space added in 
the form for free text specifications. (14) (15) In addition, the surgeon is expected to report 
any unscheduled delay of the postoperative chemotherapy regimen(s) due to the surgery or 
its complications within the first 30 days after the surgical intervention and to specify how 
long this delay lasted (in days). (11)  
















We created the first INSRF with intercontinental consensus for the structured and uniform 
reporting of all NBL-related surgical procedures and their outcomes. Due to the various 
locations of NBL and frequent encasement or infiltration of vital structures and organs, the 
surgical treatment of NBL may be highly challenging with important operative morbidity and 
even mortality.(9) (16) In localized NBL, the impact of surgical resection is well established 
and surgical resection is an important part in the multimodal treatment protocols. (17) (18)  
In high-risk NBL and especially in case of distant metastatic disease, the role of surgical 
resection remains an unsolved issue even after more than 25 years of debate, with many 
authors favoring complete or gross total resection of the primary tumor (10, 11, 19) (20) (21) 
(19) (22) (23) (24) - while other authors question the role of aggressive surgical resection for 
high-risk NBL. (9) (11, 12) (25) The reasons for these contradictory conclusions are linked to 
differences in protocols, especially indication, dose and field of adjuvant radiotherapy (26) , 
but also to the subjective appraisal of the completeness of resection, which relies 
predominantly on the surgeon’s report. The assessment of the post-operative residue on 
imaging is not standardized and differently taken into account across the cooperative 
protocols. (19, 25, 27) 
Postoperative Irradiation has an important role in the multimodal treatment of high-risk NBL 
but is implicated in numerous late toxicities, including impairment in musculoskeletal growth, 
fertility, cardiopulmonary function as well as endocrinopathies, bladder dysfunction poor 
psychosocial health and secondary malignancies. (24) The new SIOPEN HR-NBL2 protocol 
will randomize patients with macroscopic residual disease to receive a radiation boost of 36 
Gray (Gy) on post-operative residue, in addition to the baseline irradiation field of 21 Gy 
(depending on the preoperative tumor volume). (unpublished data) The patient will be 
considered to have no macroscopic residue at the time of radiotherapy if, cumulatively: 







- the postoperative MRI (or CT scan, if no MRI available) shows no definite residual 
tumour and 
- the postoperative metaiodobenzylguanidine (MIBG) scan shows no residual tumour 
and  
- the surgical report mentions a complete or minimal residual resection (< 5 cm3 residual 
tumour remaining, according to international consensus (unpublished data) agreed 
upon during joint meetings with the surgeons and oncologists of the SIOPEN, COG 
and GPOH Surgical Committees (Fig.2). 
 
Postoperative treatment will therefore rely on the surgeon’s estimation and image-based 
description of the residue. 
A recent analysis of the COG A3973 data did not show a statistically significant difference in 
outcomes based on the extent of prophylactic lymph node irradiation, regardless of the 
degree of surgical resection. (24)  While awaiting the results of the COG phase 3 trial 
ANBL0532, lowering the volume of postoperative irradiation and adapting an eventual boost 
on postoperative residue may also become part of upcoming COG NBL trials. (24) 
(unpublished data, personal communication)  
Adequate documentation by the surgeon of the extent of surgical resection and of the volume 
and localization of postoperative residue, will therefore become essential and will need to 
rely on uniform, structured reporting, guided by clear-cut, unequivocal definitions. (12)  
Recent analysis of 220 patients in the COG A3973 study (evaluating the impact of extent of 
primary tumor resection on local progression and survival and the assessed concordance 
between clinical and central imaging review-based assessments of resection extent), 
revealed however an important discordance (37%) between the operating surgeon’s 
assessment of the extent of resection and imaging-aided assessment. (19) This may be 
related to the pitfalls of narrative operative reports (NORs) as their content is not 







standardized nor regulated and may therefore be of variable quality.(28) (29) In cancer 
surgery, several authors have recently pointed out that NORs are seldom complete and may 
be of poor quality (29) (30) (31) (32) (33) (34) suggesting the development and use of 
standardized operative reports, also known as synoptic operative reports (SORs). Electronic 
SORs have been developed and implemented with proven benefit and multiple studies 
proving a gain in time. (35) In addition, structured operative reporting may even be beneficial 
for surgical education. (36)  
The first version of the INSRF presented here is not intended to be a SOR : it is at present a 
standardized surgical report form, conceived as a structured checklist for the uniform 
registration of important variables and relevant clinical information on the surgery of NBL and 
its immediate outcomes. The obligatory standardized registration of intra- and post-operative 
complications according to the Clavien-Dindo classification (14) (15) will improve the quality 
of data and facilitate even more the international comparison of different surgical timings, 
approaches, extents of resection and their outcomes. (19)  
 
As the INSRF incorporates standardized reporting of the preoperative post-chemotherapy 
IDRFs, it will also aid in the analysis of the role of pre- versus post-chemotherapy IDRFs and 
tumor volumes. (4) (7) (8, 12) (37) (38) 
Furthermore, the INSRF may be used as well for the reporting of surgical interventions of 
other neuroblastic tumors (i.e. ganglioneuroblastoma, ganglioneuroma,…) - where there is 
also still controversy on the approach, extent and timing of surgical treatment. (8) (37) 
 
After its use by the members of the core working party group, confirming the feasibility, user-
friendliness and completeness of the INSRF, next steps in this joint international 
collaboration will be the further implementation into clinical practice, by the members of the 
surgical committees of SIOPEN, COG and GPOH, to collect feedback from the individual 







users and further study adherence to the form. Interested pediatric surgical oncologists from 
other continents are also kindly invited to join this project. Development of an electronic web-
based INSRF is highly recommended to allow surgeons to fill out the form immediately after 
surgery, warranting adherence and the quality of data. The inclusion of an automated 
reminder to the surgeon 30 days after the operation to complete the registration of 
postoperative complications will ensure, as it was demonstrated in adult SORs for cancer 
(39) , higher rates of essential data completeness, intra- and interobserver reliability and 
faster and more efficient data entry.  
 
The INSRF is highly compatible with different treatment protocols for localized, intermediate 
and high-risk NBL. Its systematic incorporation in the new upcoming international NBL 
protocols of all cooperative groups will allow better analysis and definition of the surgical 
strategy in NBL treatment and comparison of local control modalities between international 
and cooperative groups.  
 
In conclusion, the INSRF is the first attempt towards a universal operative report form for the 
structured and uniform reporting of all NBL-related surgical procedures. By documenting 
important perioperative data and outcomes, the INSRF will facilitate the analysis of the 
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LEGENDS FOR FIGURES 
 
Figure 1: Radiogenomics classification of neuroblastoma by anatomical localization of the 
primary tumor: compartmental versus sympathetic chain classification with respective 





Figure 2: The International Neuroblastoma Surgical Report Form (INSRF): paper form on 5 
pages. 
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